Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $2.1 million.

  • Krystal Biotech's Capital Expenditures rose 94341.46% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $12.0 million, marking a year-over-year increase of 4064.96%. This contributed to the annual value of $12.0 million for FY2025, which is 4064.96% up from last year.
  • As of Q4 2025, Krystal Biotech's Capital Expenditures stood at $2.1 million, which was up 94341.46% from $1.7 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Capital Expenditures ranged from a high of $40.9 million in Q4 2021 and a low of -$867000.0 during Q2 2023
  • Over the past 5 years, Krystal Biotech's median Capital Expenditures value was $3.9 million (recorded in 2021), while the average stood at $7.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 36285.71% in 2024, then soared by 160000.0% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Capital Expenditures stood at $40.9 million in 2021, then tumbled by 87.24% to $5.2 million in 2022, then plummeted by 86.66% to $696000.0 in 2023, then plummeted by 70.55% to $205000.0 in 2024, then soared by 943.41% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q4 2025, $1.7 million for Q3 2025, and $1.9 million during Q2 2025.